The OJC Episode 48: Procrastination and P Values

Pinterest LinkedIn Tumblr +

The Oncology Journal Club Episode 48: Procrastination and P Values
Welcome to another entertaining and informative episode. We’re all about the P’s this week! Procrastination, P Values and yes, peeing.

Eva Segelov talks us through avoiding common P Value pitfalls and understanding statistical significance. Craig Underhill looks at Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer. And Hans Prenen talks us through a fascinating study exploring how EGFR activation limits the response of liver cancer to Lenvatinib.

Quick bites are as diverse as ever and you’ll learn why procrastination is good for creativity in the Amazing Article of the week…

We hope you enjoy listening… drop us a line on Twitter with any comments @oncologynewsaus

This Week’s Papers:

  1. Jin H, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021 Jul;595(7869):730-734. doi: 10.1038/s41586-021-03741-7. Epub 2021 Jul 21. PMID: 34290403. Access online here.
  2. Francini E, et al. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021 Jul 1;4(7):e2116536. doi: 10.1001/jamanetworkopen.2021.16536. PMID: 34292336. Access online here.
  3. Takvorian SU, et al. Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes. JAMA Netw Open. 2021 Jul 1;4(7):e2117159. doi: 10.1001/jamanetworkopen.2021.17159. PMID: 34292339. Access online here.
  4. Robinson R, et al. Understanding Statistical Significance and Avoiding Common Pitfalls. Clin Oncol (R Coll Radiol). 2021 Jun 29:S0936-6555(21)00228-4. doi: 10.1016/j.clon.2021.06.008. Epub ahead of print. PMID: 34215450. Access online here.

This Week’s Quick Bites:

  1. Bellone, S. et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals of Oncology, Volume 32, Issue 8, 1045 – 1046. Access online here.
  2. Kelley RK, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555. Epub ahead of print. PMID: 34292792. Access online here.
  3. Moss JG, et al; CAVA trial group. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet. 2021 Jul 31;398(10298):403-415. doi: 10.1016/S0140-6736(21)00766-2. Epub 2021 Jul 21. PMID: 34297997. Access online here.
  4. Goshen-Lago T,et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021 Jul 8:e212675. doi: 10.1001/jamaoncol.2021.2675. Epub ahead of print. PMID: 34236381; PMCID: PMC8267843. Access online here.
  5. Lopez Bernal, J., et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. NEJM. July 21, 2021. DOI: 10.1056/NEJMoa2108891. Access online here.
  6. Franzoi, M. A. et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. The Lancet Oncology, Volume 22, Issue 7, e303 – e313. Access online here.
  7. Raghav, K., et al. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery. July 14, 2021. Access online here.
  8. Brose, M.S., et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. July 05, 2021DOI: Access online here..
  9. Reddy, N.K. et al. Right to Try, expanded access use, Project Facilitate, and clinical trial reform. Annals of Oncology, June 21, 2021 DOI: Access online here.
  10. Kann BH, et al. Artificial intelligence for clinical oncology. Cancer Cell. 2021 Jul 12;39(7):916-927. doi: 10.1016/j.ccell.2021.04.002. Epub 2021 Apr 29. PMID: 33930310; PMCID: PMC8282694. Access online here.

Amazing Article of the Week:

Shin, J., et al. When Putting Work Off Pays Off: The Curvilinear Relationship between Procrastination and Creativity. Academy of Management Journal, Vol. 64, No. 3. Access online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Kristi Milley and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.